Portal de Periódicos da CAPES

Variability in the Interpretation of Transmitted Genotypic HIV-1 Drug Resistance and Prediction of Virological Outcomes of the Initial Haart by Distinct Systems

2004; SAGE Publishing; Volume: 9; Issue: 5 Linguagem: Inglês

10.1177/135965350400900505

2040-2058

Andrea De Luca, Alessandro Cozzi‐Lepri, Carlo Federico Perno, Claudia Balotta, Simona Di Giambenedetto, A Poggio, Gabriella Pagano, Giulia Tositti, R Piscopo, Antonio Del Forno, Francesco Chiodo, G. Magnani, Antonella d’Arminio Monforte, Gioacchino Angarano, Andrea Antinori, Claudia Balotta, Alessandro Cozzi‐Lepri, Antonella d’Arminio Monforte, Andrea De Luca, Laura Monno, Carlo Federico Perno, Stefano Rusconi, M Montroni, G Scalise, Anna Zoli, MS Del Prete, Umberto Tirelli, Gianfranco Di Gennaro, Giuseppe Pastore, Nicoletta Ladisa, G Minafra, Fredy Suter, Cumhur Arıcı, Francesco Chiodo, Vincenzo Colangeli, C. Fiorini, O. Coronado, Giampiero Carosi, GP Cadeo, Francesco Castelli, C Minardi, D. Vangi, Giuliano Rizzardini, G Migliorino, Pe Manconi, P Piano, Teresa Ferraro, A Scerbo, Eligio Pizzigallo, Margherita D’Alessandro, Domenico Santoro, Luigi Pusterla, G Carnevale, D Galloni, Paola Viganò, Maurizio Mena, F Ghinelli, L Sighinolfi, F Leoncini, Francesco Mazzotta, Mattéo Pozzi, Sergio Lo Caputo, Gioacchino Angarano, Benvenuto Grisorio, Sergio Ferrara, Pierfrancesco Grima, Paolo Tundo, G Pagano, N Piersantelli, A. Alessandrini, R Piscopo, M Toti, Silvia Chigiotti, Fabrizio Soscia, L Tacconi, Anna Orani, P. Perini, A Scasso, M. A. Vincenti, F Chiodera, P. Castelli, Alfredo Scalzini, G Fibbia, Mauro Moroni, Adriano Lazzarin, A. Cargnel, GM Vigevani, L Caggese, Antonella d’Arminio Monforte, Daniele Repetto, Roberto Novati, Andrea Galli, Stefania Merli, C Pastecchia, M C Moioli, Roberta Esposito, C Mussini, N Abrescia, Antonio Chirianni, C Izzo, M Piazza, M De Marco, Vincenzo Montesarchio, Elio Manzillo, Graf M, A Colomba, Vincenzo Abbadessa, Tullio Prestileo, Salvatrice Mancuso, Cristiana Ferrari, P Pizzaferri, Gemma Filice, L. Minoli, Raffaele Bruno, Stefano Novati, F Balzelli, K Loso, E. Petrelli, A Cioppi, F Alberici, Andrea Ruggieri, Francesco Menichetti, Canio Martinelli, C De Stefano, Ángela Gala, G. Ballardini, E Briganti, G. Magnani, M A Ursitti, M. Arlotti, P Ortolani, Roberto Cauda, F. Dianzani, Giuseppe Ippolito, Andrea Antinori, Giovanni Antonucci, S. Delia, Philipp Narciso, Nicola Petrosillo, Vincenzo Vullo, Andrea De Luca, Simona Di Giambenedetto, Mauro Zaccarelli, R Acinapura, Patrizio De Longis, Maria Rosa Ciardi, Gianpiero D’Offizi, MP Trotta, Pasquale Noto, Miriam Lichtner, MR Capobianchi, Enrico Girardi, Patrizio Pezzotti, Giovanni Rezza, MS Mura, M Mannazzu, P Caramello, Alessandro Sinicco, M L Soŕanzo, Luisa Gennero, Mauro Sciandra, M Bonasso, PA Grossi, Claudia Basilico, A Poggio, Gabriella Bottari, Enzo Raise, S Pasquinucci, Fausto de Lalla, Giulia Tositti, Francesco Resta, A Chimienti, A Cozzi Lepri,

HIV/AIDS Research and Interventions

High level HIV-1 drug resistance in recently infected treatment-naive individuals correlates with sub-optimal virological responses to highly active antiretroviral therapy (HAART). To determine whether genotypic HIV-1 drug resistance in chronic naive patients, as interpreted by various systems, could predict the virological outcomes of HAART, isolates from patients enrolled in a prospective observational cohort (ICoNA) prior to treatment start were genotyped. Genotypic susceptibility scores (GSS) assigned to the initial HAART regimens using the interpretations of pre-therapy resistance mutations by 13 systems were related to virological outcomes. Of 415 patients, 42 (10%) had at least one major resistance mutation. According to the different interpretations, 1.9–20.5% of patients had some level of resistance to at least one drug in the initial regimen. In multivariable analysis, GSS from two systems significantly predicted the time to virological success: Rega 5.5, for each unit increase in GSS adjusted relative hazard (RH) 1.86 [95% confidence intervals (95% CI): 1.15–3.02] and hivresistanceWeb v3, RH 1.87 (95% CI: 1.00–3.48). With three other systems, GSS showed a trend towards a significant prediction of success: Retrogram 1.6, RH 2.33 (95% CI: 0.98–5.53), Menéndez 2002, RH 2.36 (95% CI: 0.97–5.72) and Stanford hivdb, RH 2.06 (95% CI: 0.94–4.49). Genotypic resistance testing coupled with adequate interpretation in chronic naive patients can usefully identify those at risk of sub-optimal virological response to HAART.